Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Royalty Pharma ( (RPRX) ) has provided an update.
On April 13, 2026, Revolution Medicines reported positive Phase 3 results for its RAS(ON) inhibitor daraxonrasib in previously treated metastatic pancreatic cancer, fulfilling primary and key secondary endpoints and supporting planned global regulatory filings. The data activated a second $250 million tranche under a June 2025, $2 billion funding pact with Royalty Pharma, expanding its synthetic royalty stake and access to an associated $750 million term loan structure.
Following the new milestone, Royalty Pharma now holds tiered royalties on daraxonrasib (and potentially zoldonrasib in overlapping uses) ranging from 4.55% on initial sales up to 1.00% at higher revenue tiers, with rates rising as high as 7.80% on early sales if Revolution Medicines draws the remaining synthetic royalty funding. The structure positions Royalty Pharma to benefit materially from potential commercial success while providing Revolution Medicines with substantial optional capital tied to future regulatory, clinical and sales milestones for daraxonrasib.
The most recent analyst rating on (RPRX) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Royalty Pharma stock, see the RPRX Stock Forecast page.
Spark’s Take on RPRX Stock
According to Spark, TipRanks’ AI Analyst, RPRX is a Outperform.
The score is led by strong cash generation and high profitability, supported by constructive price trends. It is held back by leverage and a more moderate 2026 outlook (lower milestone receipts and higher interest costs), with valuation also not especially cheap at ~25x earnings.
To see Spark’s full report on RPRX stock, click here.
More about Royalty Pharma
Royalty Pharma is a specialized investment company in the biopharmaceutical sector that acquires and finances royalties on innovative medicines. Its business model focuses on providing large-scale, non-dilutive funding to drug developers in exchange for tiered royalty interests on future product sales, giving investors exposure to late-stage and commercial therapies while supplying partners with growth capital.
Average Trading Volume: 3,576,081
Technical Sentiment Signal: Buy
Current Market Cap: $27.63B
For a thorough assessment of RPRX stock, go to TipRanks’ Stock Analysis page.